TOKYO, Mar 31 (Pulse News Wire) – RIBOMIC Inc. (4591.T) announced today that it has concluded its joint research agreement with Mitsubishi Chemical Science Co., Ltd..
The collaboration, which began on January 18, 2019, aimed to develop cosmetic ingredient candidates through aptamer creation. Both companies completed the development of targeted aptamers and filed a joint patent application based on their findings. The termination of the contract marks a significant milestone in the project, achieving notable results despite concluding the formal partnership. Moving forward, RIBOMIC and Mitsubishi Chemical Science plan to negotiate and deliberate on the handling and utilization of the jointly filed patents, potentially involving licensing agreements with third parties. Mitsubishi Chemical Science Co., Ltd., headquartered at 1-3, Tokyo Hōzuka Building, 14th Floor, was established on June 12, 1954, with a capital of ¥1.399 billion. Its primary activities include manufacturing, processing, trading, importing, exporting, and researching various products such as condiments, sugar alcohols, sweeteners, quality improvers, yeast extracts, yeast-related materials, confectionery spirits, health ingredients, and cosmetics.
Mitsubishi Chemical Science Holdings Co., Ltd. holds 100% of the shares. Notably, Vitamin C60 BioResearch Co., Ltd. merged into Mitsubishi Chemical Science Co., Ltd. on April 1, 2024. There will be no impact on RIBOMIC's fiscal year 2026 consolidated earnings due to this agreement conclusion.
🟢 Confidence: High AI-translated content.